Cartilage tumours and bone development: Molecular pathology and possible therapeutic targets

Nature Reviews Cancer

Volumn 10, Issue 7, 2010, Pages 481-488

  Bovée, Judith V M G ^a   Hogendoorn, Pancras C W ^a   Wunder, Jay S ^b,c   Alman, Benjamin A ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALENDRONIC ACID; BIBR 1532; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CYCLIN DEPENDENT KINASE 4; CYCLOPAMINE; DASATINIB; DEPSIPEPTIDE; EXEMESTANE; HYPOXIA INDUCIBLE FACTOR; IMATINIB; MATRIX METALLOPROTEINASE; MINODRONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLERIXAFOR; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; TELOMERASE INHIBITOR; TRIPARANOL; UNCLASSIFIED DRUG; VORINOSTAT;

BONE DEVELOPMENT; CARTILAGE TUMOR; CHONDROSARCOMA; CYTOGENETICS; ENCHONDROMA; GENE EXPRESSION PROFILING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; NONHUMAN; OSTEOCHONDROMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DEVELOPMENT; BONE NEOPLASMS; CARTILAGE; CHONDROSARCOMA; GENE EXPRESSION REGULATION; HUMANS; MICE; OSTEOCHONDROMA; PATHOLOGY, MOLECULAR;

EID: 77954030485     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2869     Document Type: Review

References (83)

1. Fletcher, C. D. M., Unni, K. K. & Mertens, F. (eds). in World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. 234-257 (IARC Press, Lyon. France, 2002).
2. Kronenberg, H. M. Developmental regulation of the growth plate. Nature 423, 332-336 (2003).
3. Tiet, T. D. & Alman, B. A. Developmental pathways in musculoskeletal neoplasia: involvement of the Indian Hedgehog-parathyroid hormone-related protein pathway. Pediatr. Res. 53, 539-543 (2003).
4. Pathi, S., Rutenberg, J. B., Johnson, R. L. & Vortkamp, A. Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev. Biol. 209, 239-253 (1999).
5. Lyons, K. M., Pelton, R. W. & Hogan, B. L. Patterns of expression of murine Vgr-1 and BMP-2a RNA suggest that transforming growth factor-beta-like genes coordinately regulate aspects of embryonic development. Genes Dev. 3, 1657-1668 (1989).
6. Bitgood, M. J. & McMahon, A. P. Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172, 126-138 (1995).
7. St-Jacques, B., Hammerschmidt, M. & McMahon, A. P. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072-2086 (1999).
8. Minina, E. et al. BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 128, 4523-4534 (2001).
9. Schwartz, H. S. et al. The malignant potential of enchondromatosis. J. Bone Joint Surg. Am. 69, 269-274 (1987).
10. Tiet, T. D. et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am. J. Pathol. 168, 321-330 (2006).
11. Schrage, Y. M. et al. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am. J. Pathol. 174, 979-988 (2009).
12. Hopyan, S. et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nature Genet. 30, 306-310 (2002).
13. Couvineau, A. et al. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum. Mol. Genet. 17, 2766-2775 (2008).
14. van Beerendonk, H. M. et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J. Pathol. 202, 359-366 (2004).
15. Bovée, J. V. M. G. & Hogendoorn, P. C. W. Multiple osteochondromas. in World Health Organization Classification of Tumours. Pathology and Genetics Of Tumours of Soft Tissue and Bone (eds Fletcher, C. D. M., Unni, K. K. & Mertens, F.) 360-362 (IARC Press, Lyon, France, 2002).
16. Bovée, J. V. M. G. Multiple osteochondromas. Orphanet. J. Rare Dis. 3, 3 (2008).
17. Jennes, I. et al. Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum. Mutat. 30, 1620-1627 (2009).
18. Bovée, J. V. M. G. et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am. J. Hum. Genet. 65, 689-698 (1999).
19. Hameetman, L. et al. The Role of EXT1 in non hereditary osteochondroma: identification of homozygous deletions. J. Natl Cancer Inst. 99, 396-406 (2007).
20. Jones, K. B. et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc. Natl Acad. Sci. USA 107, 2054-2059 (2010).
21. Bovee, J. V. M. G. EXTra hit for mouse osteochondroma. Proc. Natl Acad. Sci. USA 107, 1813-1814 (2010).
22. McCormick, C. et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nature Genet. 19, 158-161 (1998).
23. Koziel, L., Kunath, M., Kelly, O. G. & Vortkamp, A. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev. Cell 6, 801-813 (2004).
24. Hameetman, L. et al. Decreased EXT expression and intracellular accumulation of HSPG in osteochondromas and peripheral chondrosarcomas. J. Pathol. 211, 399-409 (2007).
25. Benoist-Lasselin, C. et al. Defective chondrocyte proliferation and differentiation in osteochondromas of MHE patients. Bone 39, 17-26 (2006).
26. Clement, A. et al. Regulation of zebrafish skeletogenesis by ext2/dackel and papst1/pinscher. PLoS. Genet. 4, e1000136 (2008).
27. Fiorenza, F. et al. Risk factors for survival and local control in chondrosarcoma of bone. J. Bone Joint Surg. B r. 84, 93-99 (2002).
28. Ayala, G., Liu, C., Nicosia, R., Horowitz, S. & Lackman, R. Microvasculature and VEGF expression in cartilaginous tumors. Hum. Pathol. 31, 341-346 (2000).
29. Geirnaerdt, M. J., Hogendoorn, P. C. W., Bloem, J. L., Taminiau, A. H. M. & Van der Woude, H. J. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 214, 539-546 (2000).
30. Eefting, D. et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am. J. Surg. Pathol. 33, 50-57 (2009)
31. Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J. Bone Joint Surg. Am. 89, 2113-2123 (2007).
32. Gelderblom, H. et al. The clinical approach towards chondrosarcoma. Oncologist 13, 320-329 (2008).
33. Riedel, R. F. et al. The clinical management of chondrosarcoma. Curr. Treat Options Oncol. 10, 94-106 (2009).
34. Lee, F. Y. et al. Chondrosarcoma of bone: an assessment of outcome. J. Bone Joint Surg. Am. 81, 326-338 (1999).
35. Hameetman, L. et al. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog (IHH) signalling. J. Pathol. 209, 501-511 (2006).
36. Rudin, C. M. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178 (2009).
37. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009).
38. Alman, B. A. & Wunder, J. S. Parathyroid hormone-related protein regulates glioma-associated oncogene transcriptional activation: lessons learned from bone development and cartilage neoplasia. Ann. NY Acad. Sci. 1144, 36-41 (2008).
39. Ho, L. et al. Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16, 126-136 (2009).
40. Olmos, D. et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2, 129-135 (2010).
41. Bovée, J. V. M. G. et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosom. Cancer 26, 237-246 (1999).
42. Tallini, G. et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J. Pathol.196, 194-203 (2002).
43. Rozeman, L. B. et al. Array-CGH of central chondrosarcoma: identification of RPS6 and CDK4 as candidate target genes for genomic aberrations. Cancer 107, 380-388 (2006).
44. Schrage, Y.M. et al. Central chondrosarcoma progression is associated with pRb pathway alterations; CDK4 downregulation and p16 overexpression inhibit cell growth in vitro. J. Cell. Mol. Med. 13, 2843-2852 (2009).
45. Larramendy, M. L. et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am. J. Pathol. 150, 685-691 (1997).
46. Bovée, J. V. M. G. et al. Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. Diagn. Mol. Pathol. 10, 228-236 (2001).
47. Asp, J. et al. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int. J. Cancer 85, 782-786 (2000).
48. Asp, J., Inerot, S., Block, J. A. & Lindahl, A. Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma. J. Orthop. Res. 19, 149-154 (2001).
49. Rozeman, L. B. et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J. Pathol. 205, 476-482 (2005).
50. Schrage, Y. M. et al. Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment. Cancer Res. 69, 6216-6222 (2009).
51. Jang, J. H. & Chung, C. P. Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett. 229, 101-105 (2005).
52. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550-562 (2009).
53. Bussink, J., van der Kogel, A. J. & Kaanders, J. H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 9, 288-296 (2008).
54. Lin, C., Meitner, P. A. & Terek, R. M. PTEN mutation is rare in chondrosarcoma. Diagn. Mol. Pathol. 11, 22-26 (2002).
55. Lin, C., McGough, R., Aswad, B., Block, J. A. & Terek, R. Hypoxia induces HIF-1α and VEGF expression in chondrosarcoma cells and chondrocytes. J. Orthop. Res. 22, 1175-1181 (2004).
56. Kalinski, T. et al. Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. Cancer 106, 2028-2038 (2006).
57. McGough, R. L., Lin, C., Meitner, P., Aswad, B. I. & Terek, R. M. Angiogenic cytokines in cartilage tumors. Clin. Orthop. 397, 62-69 (2002).
58. Kubo, T. et al. Expression of hypoxia-inducible factor-1α and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J. Bone Joint Surg. Br. 90, 364-370 (2008).
59. Bovée, J. V. M. G., Van den Broek, L. J. C. M., Cleton-Jansen, A. M. & Hogendoorn, P. C. W. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab. Invest. 80, 1925-1933 (2000).
60. Moussavi-Harami, F. et al. Intrinsic radiation resistance in human chondrosarcoma cells. Biochem. Biophys. Res. Commun. 346, 379-385 (2006).
61. Boeuf, S., Bovee, J. V. M. G., Lehner, B., Hogendoorn, P. C. W. & Richter, W. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology 56, 641-651 (2009).
62. Rozeman, L. B. et al. cDNA expression profiling of central chondrosarcomas: Ollier disease resembles solitary tumors and alteration in genes coding for energy metabolism with increasing grade. J. Pathol. 207, 61-71 (2005).
63. Wyman, J. J. et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J. Orthop. Res. 17, 935-940 (1999).
64. Terek, R. M. et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J. Orthop. Res. 16, 585-590 (1998).
65. Rosier, R. N. et al. P-glycoprotein expression in cartilaginous tumors. J. Surg. Oncol. 65, 95-105 (1997).
66. Kim, D. W. et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol. Cancer 8, 28 (2009).
67. Jiang, X. et al. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J. Cell. Physiol. 202, 723-730 (2005).
68. Bovée, J. V. M. G. et al. Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. Am. J. Pathol. 157, 587-1595 (2000).
69. Schrage, Y. M. et al. COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur. J. Cancer 46, 616-624 (2010).
70. Geirnardt, M. J. et al. Usefullness of radiography in differentiating enchondroma from central grade I chondrosarcoma. Am. J. Roentgenol. 169, 1097-1104 (1997).
71. Mulder, J. D., Schütte, H. E., Kroon, H. M. & Taconis, W. K. Radiologic Atlas of Bone Tumors. 2nd edn (Elsevier, Amsterdam, 1993).
72. Miyaji, T. et al. Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett. 199, 147-155 (2003).
73. Cleton-Jansen, A. M. et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin. Cancer Res. 11, 8028-8035 (2005).
74. Fong, Y. C. et al. 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J. Orthop. Res. 25, 1106-1114 (2007).
75. Klenke, F. M. et al. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 7, 49 (2007).
76. Sakimura, R. et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin. Cancer Res. 13, 275-282 (2007).
77. Yamamoto, S. et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 28, 1585-1591 (2008).
78. 2 is associated with altered expression of Bax/Bcl-xL and p21. Biochem. Biophys. Res. Commun. 328, 375-382 (2005).
79. Lai, T. J. et al. Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol. Sin. 28, 1231-1235 (2007).
80. Kubo, T. et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J. Orthop. Res. 24, 1138-1144 (2006).
81. Parsch, D., Brassat, U., Brummendorf, T. H. & Fellenberg, J. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest. 26, 590-596 (2008).
82. Tomek, S. et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur. J. Cancer 39, 1318-1329 (2003).
83. Sun, X., Wei, L., Chen, Q. & Terek, R. M. CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol. Cancer 9, 17 (2010).